Gaofu team: To deal with mutation strains such as BA.4 and BA.5, you need to reinforce the vaccine that needs to be updated

On July 6, "New England Medical Journal" published an article "Academician Gao Fu and the ZF2001 vaccine for the Chinese Academician Team of the Institute of Microbiology of the Chinese Academy of Sciences on Omikon Rong mutation". And reorganized protein vaccine (ZF2001 vaccine) for immune effects on the mutant strain of the new crown virus. Studies have shown that several commonly used vaccines in China have greatly reduced the immune effects of BA.4 and BA.5 mutations.

The article said that in order to better prevent the current mutant strains, especially the BA.4 and BA.5 mutant strains, and the immune escape from the future of mutant strains may be developed and updated.

According to the World Health Organization's latest global new crown epidemic report on July 6, the number of new crown cases in the world has risen for the fourth consecutive week, reaching the highest level since March this year. The main reason for the increase in the number of cases is infectious and immune escape The stronger Omikon BA.4 and BA.5 mutant strains have triggered a new wave of infection in the world.

The academician Gao Fu team studied and evaluated the primitive strains of the new coronal virus in serum samples of the vaccine receiver and the neutralized antibody titer of many Omikon variants including BA.4 and BA.5. These vaccinations adopt different vaccination methods: vaccination 3 doses of analog vaccine (Kexing vaccine or national medicine vaccine); vaccination of 3 doses of restructuring protein vaccine (Zhifei ZF2001); Live vaccine +1 dose recombinant protein vaccine.

Studies have found that Omikon mutant strains have strong immune escape ability. All vaccine vaccinations are significantly lower than the corresponding titer for the original plant for the neutralization of the mutant strain, where the neutral antibody titer for BA.4 and BA.5 mutant strains is the lowest.

ZF2001 and the neutral antibody of the Vacatty Vaccine of Omikon.

Specifically, the neutralization of BA.1.1 and BA.2 is similar to BA.1 (within the range of 1.5). Compared with BA.2, BA.2.12.1 has an additional L452Q mutation in the receptor binding domain (RBD) on its spiny protein, so the neutrality rate is low, 1.4-1.7 times. In each vaccination group, the neutral antibody titer of the BA.4 and BA.5 variants is 2.1-2.6 times lower than that of the BA.2 mutant. This discovery shows that the two mutations of RBD's L452R and F486V leading to the low efficiency of antibodies caused by the current -based vaccine -based vaccine -based vaccine.

The sequence enhanced inoculation group and the antibody titer higher than the three -needle surgery group

Studies have found that neutralizing antibodies increased with the increase between the second agent and the third agent. The second dose and the third dose of the third dose are 4-6 months. Compared with the two vaccinations with two inoculation intervals, the neutral and antibody drops of the original plant separation Double, the neutral and antibody titration of all Omikon variants is about 30 times higher.

The vaccine in the long interval group is 100%serum positive to all Omir Rong mutant strains. Among the serum samples obtained in the last dose of the long interval group, 6 months later, the neutral antibody titer and serum reaction positive rate of all Omikon mutant strains higher than the last dose of the short interval group in the last dose of the short interval group was Obtained serum sample.

In addition, the inoculation group of the acceptance of the sequence (that is, the 2 -needle vaccine+1 needle restructuring protein vaccine) is higher than that of the neutral and antibody titration of the original strain and all mutant strains than the vaccination group of the three -pin invasive vaccine.

Responsible editor: Shi Jian | Audit: Li Zhen | Director: Wan Junwei

- END -